PIONEERING A NEW CLASS OF DENDRITIC
Cell-TARGETING IMMUNOTHERAPIES

Led by a seasoned management team with internationally renowned medical, industrial, and business expertise.

Learn More
Covid-19 Vaccine Laboratory

About us

LinKinVax is a French clinical-stage company developing a versatile dendritic cell (DC)-targeting immunotherapy platform.

Learn More

RESEARCH & DEVELOPMENT

The discovery of dendritic cells’ role in adaptative immunity system led to a Nobel Prize in 2011.

Now we have several immunotherapies in or entering clinical trials. 

+
+

Press releases

LinKinVax and Gustave Roussy announced first patient dosedin Phase I/IIa clinical study on HPV.DCVax in HPV-positiveoropharyngeal cancer

See press release

LinKinVax completes first batch production of “pancov”,its next generation multi-variant vaccine against covid and other coronaviruses

See press release
see more

NEWS

September 19, 2023

Vaccin thérapeutique : un premier patient traité pour un canceroropharyngé HPV-positif dans un essai à Gustave Roussy

CLICK HERE
PDF LINK
July 24, 2023

LinkinVAX completes first batch of ‘PanCov’ vaccine to prevent COVID-19

CLICK HERE
April 24, 2023

UNE PLATEFORME VACCINALE DE CLASSE MONDIALE

PDF LINK
April 11, 2023

Le Figaro – Vaccin contre le VIH : des résultats précoces encourageants en France

CLICK HERE
April 11, 2023

TF1 : Essais cliniques contre le VIH au journal de 13h

CLICK HERE
April 6, 2023

Laboratoires pharmaceutiques: l’arrivée des nouveaux vaccins bouleverse la hiérarchie mondiale

PDF LINK
see more

Interested in our project?

CONTACT US